SecBot SecBot

XRTX

XORTX Therapeutics Inc.
Nasdaq· Pharmaceutical Preparations· Inc. A1· CIK 0001729214 Biotech & Drug Discovery
$0.8500 −0.07 (−7.61%)
Oct 26 4:00 PM ET · prev $0.9200
Market cap
$1.8M
Nano cap
1 year
−74.4%
from $3.32 · Oct 27
30 days
−50.3%
from $1.71
52-week range
$0.8500–3.32
at the low
Avg volume 20D
1.60M
Oct 9 spike 18.65M
Short interest
61.5K
≈3.4% of shares · −19.8%
Days to cover
1.0
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
16
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 1 bearish · 0 bullish · 1 mixed · 5 neutral oldest → newest, height = score
Avg score ·High conf. 4/7
Strongest BEARISH XORTX Therapeutics re-engages IR Agency LLC for a $2.5M marketing and advertising campaign over three…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 1 trimmed or exited.

  • Short sellersCOVERING

    Short interest −19.8% to 61.5K shares. 1.0 days to cover, ≈3.4% of shares.

  • TrendDOWNTREND

    53% below its 50-day average. New closing low $0.8500 on Oct 26.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 9.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
Clearstead Advisors, LLCNEAR_EXIT55$120.00
UBS Group AGDOUBLED1,401$787.00
CITADEL ADVISORS LLCDOUBLED86,326$69.9K
UBS Group AGNEAR_EXIT234$190.00
NATIONAL BANK OF CANADA /FI/DOUBLED3,934$3.9K
NATIONAL BANK OF CANADA /FI/NEAR_EXIT174$150.00
ROYAL BANK OF CANADADOUBLED1,493$2.0K
NATIONAL BANK OF CANADA /FI/TRIM1,613$1.7K

Quarterly 13F filings are due 45 days after each quarter ends.

Reddit
Recent posts
r/pennystocks Neutral 17d ago
09 OCT WHAT ARE THE BIGGEST WINNERS AND WHY ?
4 upvotes · 1 comments
All social signals and their track records

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 18, 2026
Earnings
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company’s regulatory path…
Sep 8, 2026
Delisting
XORTX Re-Engages Investor Relations Program
CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) announces that, following completion of…
Aug 28, 2026
Contract
XORTX Announces Termination and Postponement of Investor Relations Program
CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt…
Jul 31, 2026
Press release
XORTX Announces Director Resignation
CALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt…
Jun 12, 2026
Activist
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt…

Short side

FINRA· Sep 30, 2026
61,535
shares short
-19.8%
vs prior settlement
1.0
days to cover
≈3.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 8, 2026 SEC
XORTX announced plans to file a Clinical Trial Application (CTA) with Health Canada for its XRx-026 gout program…
6-K — Impact 3/10
Sep 18, 2026 SEC
XORTX announced plans to submit an IND to the FDA in Q4 2026 for its XRx-026 gout program (XORLO formulation of…
6-K — Impact 4/10
Sep 18, 2026 SEC
XORTX Therapeutics announced plans to submit an IND to the FDA in Q4 2026 for its XRx-026 gout program (XORLO…
PRESS-RELEASE — Impact 4/10
Sep 18, 2026 Earnings
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of
Jun 30, 2026 Inst.
Clearstead Advisors, LLC — NEAR_EXIT
55 shares ($120.00)
May 14, 2026 Press
XORTX Therapeutics priced a public offering of ~2.66M shares at $1.88/share for $5M gross proceeds, representing…
Impact 6/10
Apr 13, 2026 Press
XORTX Therapeutics has closed its acquisition of Vectus Biosystems' renal anti-fibrotic program, including the pre-IND…
Impact 7/10
Dec 31, 2025 Inst.
UBS Group AG — DOUBLED
1,401 shares ($787.00)

SecBot reports

16 filings · 5 press releases · 1 bullish · 4 bearish · 1 mixed · 10 neutral
All XRTX filing & press-release reports (21)